chevron_leftBack
A
As of 24 April 2025, Avadel Pharmaceuticals plc has a market cap of $802.99M USD, ranking #9269 globally and #37 in Ireland. It ranks #896 in the Healthcare sector, and #208 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$802.99MUSD
Enterprise Value
$768.06MUSD
Revenue (TTM)
$169.12MUSD
EBITDA (TTM)
-$39.72MUSD
Net Income (TTM)
-$48.83MUSD
EBITDA Margin
-23%
Profit Margin
-29%
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Gregory Divis
open_in_new
Employees
188
Founded
2015
IPO
07 Jun 1996
Website
avadel.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.7% | 2.2% | -2.8% | 4.1% | -39% | -52% |
Upcoming Earnings
Earnings Date
Wed, May 7
Earnings Time
sunny
Before Open
EPS Estimate
-$0.0600
Revenue Estimate
$50.5M
86% yoy
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
AVDL
Avadel Pharmaceuticals PLC
ISIN: IE00BDGMC594
Shares Out.:
Shares Outstanding:
96.629M1
Shares Float:
88.273M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
8.33 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
Country |
|---|---|---|
Alkermes plc
NASDAQ: ALKS
|
$4.48B
457%
|
|
Perrigo Company plc
NYSE: PRGO
|
$3.38B
320%
|
|
Malin Corporation plc
ISE: MLC
|
$44.83M
-94%
39.4M EUR
|
